How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about pembrolizumab with axitinib

Marketing authorisation indication

2.1 Pembrolizumab (Keytruda, Merck Sharp & Dohme), in combination with axitinib (Inlyta, Pfizer), is indicated 'for the first-line treatment of advanced renal cell carcinoma (RCC) in adults'.

Dosage in the marketing authorisation

2.2 Pembrolizumab, 200 mg intravenously every 3 weeks, with axitinib, 5 mg orally twice daily.

Price

2.3 The list price of pembrolizumab is £2,630 per 100 mg vial (excluding VAT; BNF online, assessed January 2020). The cost of a single administration is £5,260. This represents approximately 3 weeks of treatment.

The company has a commercial arrangement for pembrolizumab. This makes pembrolizumab available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

2.4 The list price of axitinib is £3,517 per 56 5 mg tablets (excluding VAT; BNF online, assessed January 2020). This represents approximately 28 days of treatment.

The company has a commercial arrangement for axitinib. This makes axitinib available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.